{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:45:21Z","timestamp":1767015921406},"reference-count":73,"publisher":"Aging and Disease","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging and disease"],"published-print":{"date-parts":[[2018]]},"DOI":"10.14336\/ad.2017.0416","type":"journal-article","created":{"date-parts":[[2018,2,8]],"date-time":"2018-02-08T02:52:40Z","timestamp":1518058360000},"page":"51","source":"Crossref","is-referenced-by-count":43,"title":["Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson\u2019s Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage"],"prefix":"10.14336","volume":"9","author":[{"given":"Jing","family":"Zou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhigang","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caiqian","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongmei","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaobo","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianjun","family":"Lu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengqiu","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Guo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinxue","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Xie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Duobin","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihui","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Penghua","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"5462","reference":[{"key":"key-10.14336\/AD.2017.0416-1","doi-asserted-by":"crossref","unstructured":"Delgado-Alvarado M, Gago B, Navalpotro-Gomez I, Jimenez-Urbieta H, Rodriguez-Oroz MC (2016). Biomarkers for dementia and mild cognitive impairment in Parkinson\u2019s disease. Mov Disord, 31: 861-881","DOI":"10.1002\/mds.26662"},{"key":"key-10.14336\/AD.2017.0416-2","doi-asserted-by":"crossref","unstructured":"Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM (2017). Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson\u2019s disease: a cohort study. Lancet Neurol, 16: 66-75","DOI":"10.1016\/S1474-4422(16)30328-3"},{"key":"key-10.14336\/AD.2017.0416-3","doi-asserted-by":"crossref","unstructured":"Yamanouchi H, Nagura H (1997). Neurological signs and frontal white matter lesions in vascular parkinsonism. A clinicopathologic study. Stroke, 28: 965-969","DOI":"10.1161\/01.STR.28.5.965"},{"key":"key-10.14336\/AD.2017.0416-4","doi-asserted-by":"crossref","unstructured":"Xu Y, Wei X, Liu X, Liao J, Lin J, Zhu C,et al. (2015). Low Cerebral Glucose Metabolism: A Potential Predictor for the Severity of Vascular Parkinsonism and Parkinson\u2019s Disease. Aging Dis, 6: 426-436","DOI":"10.14336\/AD.2015.0204"},{"key":"key-10.14336\/AD.2017.0416-5","doi-asserted-by":"crossref","unstructured":"Zhang L, Yan J, Xu Y, Long L, Zhu C, Chen X,et al. (2011). The combination of homocysteine and C-reactive protein predicts the outcomes of Chinese patients with Parkinson\u2019s disease and vascular parkinsonism. PLoS One, 6: e19333.","DOI":"10.1371\/journal.pone.0019333"},{"key":"key-10.14336\/AD.2017.0416-6","doi-asserted-by":"crossref","unstructured":"Pan M, Gao H, Long L, Xu Y, Liu M, Zou J,et al. (2013). Serum uric acid in patients with Parkinson\u2019s disease and vascular parkinsonism: a cross-sectional study. Neuroimmunomodulation, 20: 19-28","DOI":"10.1159\/000342483"},{"key":"key-10.14336\/AD.2017.0416-7","doi-asserted-by":"crossref","unstructured":"Benitez-Rivero S, Lama MJ, Huertas-Fernandez I, Alvarez de Toledo P, Caceres-Redondo MT, Martin-Rodriguez JF,et al. (2014). Clinical features and neuropsychological profile in vascular parkinsonism. J Neurol Sci, 345: 193-197","DOI":"10.1016\/j.jns.2014.07.046"},{"key":"key-10.14336\/AD.2017.0416-8","doi-asserted-by":"crossref","unstructured":"Heller J, Dogan I, Schulz JB, Reetz K (2014). Evidence for gender differences in cognition, emotion and quality of life in Parkinson\u2019s disease? Aging Dis, 5: 63-75","DOI":"10.14336\/AD.2014.050063"},{"key":"key-10.14336\/AD.2017.0416-9","doi-asserted-by":"crossref","unstructured":"Anang JB, Gagnon JF, Bertrand JA, Romenets SR, Latreille V, Panisset M,et al. (2014). Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology, 83: 1253-1260","DOI":"10.1212\/WNL.0000000000000842"},{"key":"key-10.14336\/AD.2017.0416-10","doi-asserted-by":"crossref","unstructured":"Euser SM, Hofman A, Westendorp RG, Breteler MM (2009). Serum uric acid and cognitive function and dementia. Brain, 132: 377-382","DOI":"10.1093\/brain\/awn316"},{"key":"key-10.14336\/AD.2017.0416-11","doi-asserted-by":"crossref","unstructured":"de Lau LM, Koudstaal PJ, Hofman A, Breteler MM (2005). Serum uric acid levels and the risk of Parkinson disease. Ann Neurol, 58: 797-800","DOI":"10.1002\/ana.20663"},{"key":"key-10.14336\/AD.2017.0416-12","doi-asserted-by":"crossref","unstructured":"Gonzalez-Aramburu I, Sanchez-Juan P, Jesus S, Gorostidi A, Fernandez-Juan E, Carrillo F,et al. (2013). Genetic variability related to serum uric acid concentration and risk of Parkinson\u2019s disease. Mov Disord, 28: 1737-1740","DOI":"10.1002\/mds.25507"},{"key":"key-10.14336\/AD.2017.0416-13","doi-asserted-by":"crossref","unstructured":"Thim L, May FE (2005). Structure of mammalian trefoil factors and functional insights. Cell Mol Life Sci, 62: 2956-2973","DOI":"10.1007\/s00018-005-5484-6"},{"key":"key-10.14336\/AD.2017.0416-14","doi-asserted-by":"crossref","unstructured":"Jagla W, Wiede A, Dietzmann K, Rutkowski K, Hoffmann W (2000). Co-localization of TFF3 peptide and oxytocin in the human hypothalamus. FASEB J, 14: 1126-1131","DOI":"10.1096\/fasebj.14.9.1126"},{"key":"key-10.14336\/AD.2017.0416-15","doi-asserted-by":"crossref","unstructured":"Probst JC, Zetzsche T, Weber M, Theilemann P, Skutella T, Landgraf R,et al. (1996). Human intestinal trefoil factor is expressed in human hypothalamus and pituitary: evidence for a novel neuropeptide. FASEB J, 10: 1518-1523","DOI":"10.1096\/fasebj.10.13.8940297"},{"key":"key-10.14336\/AD.2017.0416-16","doi-asserted-by":"crossref","unstructured":"Shi HS, Yin X, Song L, Guo QJ, Luo XH (2012). Neuropeptide Trefoil factor 3 improves learning and retention of novel object recognition memory in mice. Behav Brain Res, 227: 265-269","DOI":"10.1016\/j.bbr.2011.10.051"},{"key":"key-10.14336\/AD.2017.0416-17","doi-asserted-by":"crossref","unstructured":"Paterson RW, Bartlett JW, Blennow K, Fox NC, Shaw LM, Trojanowski JQ,et al. (2014). Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry, 4: e419.","DOI":"10.1038\/tp.2014.58"},{"key":"key-10.14336\/AD.2017.0416-18","doi-asserted-by":"crossref","unstructured":"Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E,et al. (2003). Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J, 17: 7-16","DOI":"10.1096\/fj.02-0201com"},{"key":"key-10.14336\/AD.2017.0416-19","doi-asserted-by":"crossref","unstructured":"Tran CP, Cook GA, Yeomans ND, Thim L, Giraud AS (1999). Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut, 44: 636-642","DOI":"10.1136\/gut.44.5.636"},{"key":"key-10.14336\/AD.2017.0416-20","doi-asserted-by":"crossref","unstructured":"Rodriguez-Oroz MC, Lage PM, Sanchez-Mut J, Lamet I, Pagonabarraga J, Toledo JB,et al. (2009). Homocysteine and cognitive impairment in Parkinson\u2019s disease: a biochemical, neuroimaging, and genetic study. Mov Disord, 24: 1437-1444","DOI":"10.1002\/mds.22522"},{"key":"key-10.14336\/AD.2017.0416-21","doi-asserted-by":"crossref","unstructured":"Shimomura T, Anan F, Masaki T, Umeno Y, Eshima N, Saikawa T,et al. (2011). Homocysteine levels are associated with hippocampus volume in type 2 diabetic patients. Eur J Clin Invest, 41: 751-758","DOI":"10.1111\/j.1365-2362.2010.02464.x"},{"key":"key-10.14336\/AD.2017.0416-22","unstructured":"Ray L, Khemka VK, Behera P, Bandyopadhyay K, Pal S, Pal K,et al. (2013). Serum Homocysteine, Dehydroepiandrosterone Sulphate and Lipoprotein (a) in Alzheimer\u2019s Disease and Vascular Dementia. Aging Dis, 4: 57-64"},{"key":"key-10.14336\/AD.2017.0416-23","doi-asserted-by":"crossref","unstructured":"Xie Y, Feng H, Peng S, Xiao J, Zhang J (2017). Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson\u2019s disease: A meta-analysis. Neurosci Lett, 636: 190-195","DOI":"10.1016\/j.neulet.2016.11.007"},{"key":"key-10.14336\/AD.2017.0416-24","doi-asserted-by":"crossref","unstructured":"Kamat PK, Kalani A, Givvimani S, Sathnur PB, Tyagi SC, Tyagi N (2013). Hydrogen sulfide attenuates neurodegeneration and neurovascular dysfunction induced by intracerebral-administered homocysteine in mice. Neuroscience, 252: 302-319","DOI":"10.1016\/j.neuroscience.2013.07.051"},{"key":"key-10.14336\/AD.2017.0416-25","doi-asserted-by":"crossref","unstructured":"Atack JR, Perry EK, Bonham JR, Candy JM, Perry RH (1986). Molecular forms of acetylcholinesterase and butyrylcholinesterase in the aged human central nervous system. J Neurochem, 47: 263-277","DOI":"10.1111\/j.1471-4159.1986.tb02858.x"},{"key":"key-10.14336\/AD.2017.0416-26","doi-asserted-by":"crossref","unstructured":"Perry EK, Perry RH, Blessed G, Tomlinson BE (1978). Changes in brain cholinesterases in senile dementia of Alzheimer type. Neuropathol Appl Neurobiol, 4: 273-277","DOI":"10.1111\/j.1365-2990.1978.tb00545.x"},{"key":"key-10.14336\/AD.2017.0416-27","doi-asserted-by":"crossref","unstructured":"Chipperfield B, Newman PM, Moyes IC (1981). Decreased erythrocyte cholinesterase activity in dementia. Lancet. 1981 Jul 25;2(8239):199.","DOI":"10.1016\/S0140-6736(81)90377-9"},{"key":"key-10.14336\/AD.2017.0416-28","doi-asserted-by":"crossref","unstructured":"Bonelli RM, Aschoff A, Niederwieser G, Heuberger C, Jirikowski G (2002). Cerebrospinal fluid tissue transglutaminase as a biochemical marker for Alzheimer\u2019s disease. Neurobiol Dis, 11: 106-110","DOI":"10.1006\/nbdi.2002.0535"},{"key":"key-10.14336\/AD.2017.0416-29","doi-asserted-by":"crossref","unstructured":"Carelli-Alinovi C, Dinarelli S, Girasole M, Misiti F (2016). Vascular dysfunction-associated with Alzheimer\u2019s disease. Clin Hemorheol Microcirc. 2016;64(4):679-687.","DOI":"10.3233\/CH-168047"},{"key":"key-10.14336\/AD.2017.0416-30","doi-asserted-by":"crossref","unstructured":"Ben Assayag E, Shenhar-Tsarfaty S, Ofek K, Soreq L, Bova I, Shopin L,et al. (2010). Serum cholinesterase activities distinguish between stroke patients and controls and predict 12-month mortality. Mol Med, 16: 278-286","DOI":"10.2119\/molmed.2010.00015"},{"key":"key-10.14336\/AD.2017.0416-31","doi-asserted-by":"crossref","unstructured":"Dunet V, Deverdun J, Charroud C, Le Bars E, Molino F, Menjot de Champfleur S,et al. (2016). Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism. AJNR Am J Neuroradiol. 37(12):2310-2316.","DOI":"10.3174\/ajnr.A4889"},{"key":"key-10.14336\/AD.2017.0416-32","doi-asserted-by":"crossref","unstructured":"Firbank MJ, Colloby SJ, Burn DJ, McKeith IG, O\u2019Brien JT (2003). Regional cerebral blood flow in Parkinson\u2019s disease with and without dementia. Neuroimage, 20: 1309-1319","DOI":"10.1016\/S1053-8119(03)00364-1"},{"key":"key-10.14336\/AD.2017.0416-33","doi-asserted-by":"crossref","unstructured":"Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K,et al. (2015). Increased CSF biomarkers of angiogenesis in Parkinson disease. Neurology, 85: 1834-1842","DOI":"10.1212\/WNL.0000000000002151"},{"key":"key-10.14336\/AD.2017.0416-34","unstructured":"Gemma C (2010). Neuroimmunomodulation and Aging. Aging Dis, 1: 169-172"},{"key":"key-10.14336\/AD.2017.0416-35","doi-asserted-by":"crossref","unstructured":"Emre M, Aarsland D, Brown R, Burn DJ, Duyckaerts C, Mizuno Y,et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson\u2019s disease. Mov Disord, 22: 1689-1707","DOI":"10.1002\/mds.21507"},{"key":"key-10.14336\/AD.2017.0416-36","doi-asserted-by":"crossref","unstructured":"Zijlmans JC, Daniel SE, Hughes AJ, Revesz T, Lees AJ (2004). Clinicopathological investigation of vascular parkinsonism, including clinical criteria for diagnosis. Mov Disord, 19: 630-640","DOI":"10.1002\/mds.20083"},{"key":"key-10.14336\/AD.2017.0416-37","doi-asserted-by":"crossref","unstructured":"Fahn S (1987). Drug treatment of hyperkinetic movement disorders. Semin Neurol, 7: 192-208","DOI":"10.1055\/s-2008-1041419"},{"key":"key-10.14336\/AD.2017.0416-38","unstructured":"Hoehn MM, Yahr MD (2001). Parkinsonism: onset, progression, and mortality. 1967. Neurology, 57: S11-26"},{"key":"key-10.14336\/AD.2017.0416-39","doi-asserted-by":"crossref","unstructured":"Li H, Zhang M, Chen L, Zhang J, Pei Z, Hu A,et al. (2010). Nonmotor symptoms are independently associated with impaired health-related quality of life in Chinese patients with Parkinson\u2019s disease. Mov Disord, 25: 2740-2746","DOI":"10.1002\/mds.23368"},{"key":"key-10.14336\/AD.2017.0416-40","doi-asserted-by":"crossref","unstructured":"Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P,et al. (2007). The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: Results from an international pilot study. Mov Disord, 22: 1901-1911","DOI":"10.1002\/mds.21596"},{"key":"key-10.14336\/AD.2017.0416-41","doi-asserted-by":"crossref","unstructured":"Folstein MF, Folstein SE, McHugh PR (1975). \"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res, 12: 189-198","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"key-10.14336\/AD.2017.0416-42","doi-asserted-by":"crossref","unstructured":"Reinoso G, Allen JC, Jr., Au WL, Seah SH, Tay KY, Tan LC (2015). Clinical evolution of Parkinson\u2019s disease and prognostic factors affecting motor progression: 9-year follow-up study. Eur J Neurol, 22: 457-463","DOI":"10.1111\/ene.12476"},{"key":"key-10.14336\/AD.2017.0416-43","doi-asserted-by":"crossref","unstructured":"Oosterveld LP, Allen JC, Jr., Ng EY, Seah SH, Tay KY, Au WL,et al. (2015). Greater motor progression in patients with Parkinson disease who carry LRRK2 risk variants. Neurology, 85: 1039-1042","DOI":"10.1212\/WNL.0000000000001953"},{"key":"key-10.14336\/AD.2017.0416-44","doi-asserted-by":"crossref","unstructured":"Ellman GL, Courtney KD, Andres V, Jr., Feather-Stone RM (1961). A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol, 7: 88-95","DOI":"10.1016\/0006-2952(61)90145-9"},{"key":"key-10.14336\/AD.2017.0416-45","doi-asserted-by":"crossref","unstructured":"Winikates J, Jankovic J (1999). Clinical correlates of vascular parkinsonism. Arch Neurol, 56: 98-102","DOI":"10.1001\/archneur.56.1.98"},{"key":"key-10.14336\/AD.2017.0416-46","doi-asserted-by":"crossref","unstructured":"Zijlmans J, Evans A, Fontes F, Katzenschlager R, Gacinovic S, Lees AJ,et al. (2007). [123I] FP-CIT spect study in vascular parkinsonism and Parkinson\u2019s disease. Mov Disord, 22: 1278-1285","DOI":"10.1002\/mds.21479"},{"key":"key-10.14336\/AD.2017.0416-47","doi-asserted-by":"crossref","unstructured":"Kalra S, Grosset DG, Benamer HT (2010). Differentiating vascular parkinsonism from idiopathic Parkinson\u2019s disease: a systematic review. Mov Disord, 25: 149-156","DOI":"10.1002\/mds.22937"},{"key":"key-10.14336\/AD.2017.0416-48","doi-asserted-by":"crossref","unstructured":"Saracchi E, Fermi S, Brighina L (2014). Emerging candidate biomarkers for Parkinson\u2019s disease: a review. Aging Dis, 5: 27-34","DOI":"10.14336\/AD.2014.050027"},{"key":"key-10.14336\/AD.2017.0416-49","doi-asserted-by":"crossref","unstructured":"Sterling NW, Lichtenstein M, Lee EY, Lewis MM, Evans A, Eslinger PJ,et al. (2016). Higher Plasma LDL-Cholesterol is Associated with Preserved Executive and Fine Motor Functions in Parkinson\u2019s Disease. Aging Dis, 7: 237-245","DOI":"10.14336\/AD.2015.1030"},{"key":"key-10.14336\/AD.2017.0416-50","doi-asserted-by":"crossref","unstructured":"von Bernhardi R, Alarcon R, Mezzano D, Fuentes P, Inestrosa NC (2005). Blood cells cholinesterase activity in early stage Alzheimer\u2019s disease and vascular dementia. Dement Geriatr Cogn Disord, 19: 204-212","DOI":"10.1159\/000083500"},{"key":"key-10.14336\/AD.2017.0416-51","doi-asserted-by":"crossref","unstructured":"Szilagyi AK, Nemeth A, Martini E, Lendvai B, Venter V (1987). Serum and CSF cholinesterase activity in various kinds of dementia. Eur Arch Psychiatry Neurol Sci, 236: 309-311","DOI":"10.1007\/BF00380958"},{"key":"key-10.14336\/AD.2017.0416-52","doi-asserted-by":"crossref","unstructured":"Bohnen NI, Muller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA,et al. (2009). History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology, 73: 1670-1676","DOI":"10.1212\/WNL.0b013e3181c1ded6"},{"key":"key-10.14336\/AD.2017.0416-53","doi-asserted-by":"crossref","unstructured":"Prins ND, Den Heijer T, Hofman A, Koudstaal PJ, Jolles J, Clarke R,et al. (2002). Homocysteine and cognitive function in the elderly: the Rotterdam Scan Study. Neurology, 59: 1375-1380","DOI":"10.1212\/01.WNL.0000032494.05619.93"},{"key":"key-10.14336\/AD.2017.0416-54","doi-asserted-by":"crossref","unstructured":"Seshadri S, Beiser A, Selhub J, Jacques PF, Rosenberg IH, D\u2019Agostino RB,et al. (2002). Plasma homocysteine as a risk factor for dementia and Alzheimer\u2019s disease. N Engl J Med, 346: 476-483","DOI":"10.1056\/NEJMoa011613"},{"key":"key-10.14336\/AD.2017.0416-55","doi-asserted-by":"crossref","unstructured":"Zoccolella S, dell\u2019Aquila C, Specchio LM, Logroscino G, Lamberti P (2010). Elevated homocysteine levels in Parkinson\u2019s Disease: is there anything besides L-dopa treatment? Curr Med Chem, 17: 213-221","DOI":"10.2174\/092986710790149774"},{"key":"key-10.14336\/AD.2017.0416-56","doi-asserted-by":"crossref","unstructured":"Xie Y, Feng H, Peng S, Xiao J, Zhang J (2017). Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson\u2019s disease: A meta-analysis. Neurosci Lett. 636:190-195.","DOI":"10.1016\/j.neulet.2016.11.007"},{"key":"key-10.14336\/AD.2017.0416-57","doi-asserted-by":"crossref","unstructured":"Baccarelli A, Zanobetti A, Martinelli I, Grillo P, Hou L, Lanzani G,et al. (2007). Air pollution, smoking, and plasma homocysteine. Environ Health Perspect, 115: 176-181","DOI":"10.1289\/ehp.9517"},{"key":"key-10.14336\/AD.2017.0416-58","doi-asserted-by":"crossref","unstructured":"Ramsey JM, Cooper JD, Bot M, Guest PC, Lamers F, Weickert CS,et al. (2016). Sex Differences in Serum Markers of Major Depressive Disorder in the Netherlands Study of Depression and Anxiety (NESDA). PLoS One, 11: e0156624.","DOI":"10.1371\/journal.pone.0156624"},{"key":"key-10.14336\/AD.2017.0416-59","doi-asserted-by":"crossref","unstructured":"Liu SQ, Roberts D, Zhang B, Ren Y, Zhang LQ, Wu YH (2013). Trefoil factor 3 as an endocrine neuroprotective factor from the liver in experimental cerebral ischemia\/reperfusion injury. PLoS One, 8(10):e77732.","DOI":"10.1371\/journal.pone.0077732"},{"key":"key-10.14336\/AD.2017.0416-60","doi-asserted-by":"crossref","unstructured":"Shinotoh H, Namba H, Yamaguchi M, Fukushi K, Nagatsuka S, Iyo M,et al. (1999). Positron emission tomographic measurement of acetylcholinesterase activity reveals differential loss of ascending cholinergic systems in Parkinson\u2019s disease and progressive supranuclear palsy. Ann Neurol, 46: 62-69","DOI":"10.1002\/1531-8249(199907)46:1<62::AID-ANA10>3.0.CO;2-P"},{"key":"key-10.14336\/AD.2017.0416-61","doi-asserted-by":"crossref","unstructured":"Bjelland I, Tell GS, Vollset SE, Refsum H, Ueland PM (2003). Folate, vitamin B12, homocysteine, and the MTHFR 677C->T polymorphism in anxiety and depression: the Hordaland Homocysteine Study. Arch Gen Psychiatry, 60: 618-626","DOI":"10.1001\/archpsyc.60.6.618"},{"key":"key-10.14336\/AD.2017.0416-62","doi-asserted-by":"crossref","unstructured":"O\u2019Suilleabhain PE, Sung V, Hernandez C, Lacritz L, Dewey RB, Jr., Bottiglieri T,et al. (2004). Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol, 61: 865-868","DOI":"10.1001\/archneur.61.6.865"},{"key":"key-10.14336\/AD.2017.0416-63","doi-asserted-by":"crossref","unstructured":"Chen D, Wei X, Zou J, Wang R, Liu X, Xu X,et al. (2015). Contra-Directional Expression of Serum Homocysteine and Uric Acid as Important Biomarkers of Multiple System Atrophy Severity: A Cross-Sectional Study. Front Cell Neurosci, 9:247.","DOI":"10.3389\/fncel.2015.00247"},{"key":"key-10.14336\/AD.2017.0416-64","doi-asserted-by":"crossref","unstructured":"Hooshmand B, Polvikoski T, Kivipelto M, Tanskanen M, Myllykangas L, Erkinjuntti T,et al. (2013). Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain, 136: 2707-2716","DOI":"10.1093\/brain\/awt206"},{"key":"key-10.14336\/AD.2017.0416-65","doi-asserted-by":"crossref","unstructured":"Obeid R, Herrmann W (2006). Mechanisms of homocysteine neurotoxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett, 580: 2994-3005","DOI":"10.1016\/j.febslet.2006.04.088"},{"key":"key-10.14336\/AD.2017.0416-66","doi-asserted-by":"crossref","unstructured":"Seshadri S (2006). Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer\u2019s disease? J Alzheimers Dis, 9: 393-398","DOI":"10.3233\/JAD-2006-9404"},{"key":"key-10.14336\/AD.2017.0416-67","doi-asserted-by":"crossref","unstructured":"Hemanth Kumar B, Arun Reddy R, Mahesh Kumar J, Dinesh Kumar B, Diwan PV (2016). Effects of fisetin on hyperhomocysteinemia-induced experimental endothelial dysfunction and vascular dementia. Can J Physiol Pharmacol: 1-11","DOI":"10.1139\/cjpp-2016-0147"},{"key":"key-10.14336\/AD.2017.0416-68","doi-asserted-by":"crossref","unstructured":"Choe YM, Sohn BK, Choi HJ, Byun MS, Seo EH, Han JY,et al. (2014). Association of homocysteine with hippocampal volume independent of cerebral amyloid and vascular burden. Neurobiol Aging, 35: 1519-1525","DOI":"10.1016\/j.neurobiolaging.2014.01.013"},{"key":"key-10.14336\/AD.2017.0416-69","doi-asserted-by":"crossref","unstructured":"Boldyrev A, Bryushkova E, Mashkina A, Vladychenskaya E (2013). Why is homocysteine toxic for the nervous and immune systems? Curr Aging Sci, 6: 29-36","DOI":"10.2174\/18746098112059990007"},{"key":"key-10.14336\/AD.2017.0416-70","doi-asserted-by":"crossref","unstructured":"Streck EL, Vieira PS, Wannmacher CM, Dutra-Filho CS, Wajner M, Wyse AT (2003). In vitro effect of homocysteine on some parameters of oxidative stress in rat hippocampus. Metab Brain Dis, 18: 147-154","DOI":"10.1023\/A:1023815119931"},{"key":"key-10.14336\/AD.2017.0416-71","doi-asserted-by":"crossref","unstructured":"Stefanello FM, Franzon R, Tagliari B, Wannmacher C, Wajner M, Wyse AT (2005). Reduction of butyrylcholinesterase activity in rat serum subjected to hyperhomocysteinemia. Metab Brain Dis, 20: 97-103","DOI":"10.1007\/s11011-005-4147-5"},{"key":"key-10.14336\/AD.2017.0416-72","doi-asserted-by":"crossref","unstructured":"Streck EL, Delwing D, Tagliari B, Matte C, Wannmacher CM, Wajner M,et al. (2003). Brain energy metabolism is compromised by the metabolites accumulating in homocystinuria. Neurochem Int, 43: 597-602","DOI":"10.1016\/S0197-0186(02)00230-9"},{"key":"key-10.14336\/AD.2017.0416-73","doi-asserted-by":"crossref","unstructured":"Scherer EB, Stefanello FM, Mattos C, Netto CA, Wyse AT (2007). Homocysteine reduces cholinesterase activity in rat and human serum. Int J Dev Neurosci, 25: 201-205","DOI":"10.1016\/j.ijdevneu.2007.03.007"}],"container-title":["Aging and disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.aginganddisease.org\/fileup\/2152-5250\/PDF\/2152-5250-2018-1-51.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T02:48:48Z","timestamp":1627613328000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.aginganddisease.org\/EN\/10.14336\/AD.2017.0416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"references-count":73,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.14336\/ad.2017.0416","relation":{},"ISSN":["2152-5250"],"issn-type":[{"value":"2152-5250","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}